TY - JOUR
T1 - Isavuconazole is effective for the treatment of experimental cryptococcal meningitis
AU - Wiederhold, Nathan P.
AU - Kovanda, Laura
AU - Najvar, Laura K.
AU - Bocanegra, Rosie
AU - Olivo, Marcos
AU - Kirkpatrick, William R.
AU - Patterson, Thomas F.
N1 - Funding Information:
We thank Arlene Farias for her help with the animal model and Dora McCarthy for assistance with the in vitro susceptibility testing. N.P.W. has received research support from Astellas, bioMérieux, Dow, F2G, Merck, Merz, Revolution Medicines, and Viamet and has served on advisory boards for Astellas, Merck, Toyama, and Viamet. T.F.P. has received research grants to the UT Health Science Center at San Antonio from Astellas, Merck, and Revolution Medicines and has served as a consultant for Amplyx, Astellas, Cidara, Gilead, Pfizer, Merck, Scynexis, Toyama, Viamet, and Vical. L.K.N. has received travel support from Viamet Pharmaceuticals, Inc. L.K. is an employee of Astellas. The other authors declare no conflicts of interest. This work, including the efforts of Nathan P. Wiederhold and Thomas F. Patterson, was funded by Astellas Pharma US (Astellas). Isavuconazonium sulfate and isavuconazole powders were provided by Basilea.
Publisher Copyright:
Copyright © 2016, American Society for Microbiology. All Rights Reserved.
PY - 2016/9/1
Y1 - 2016/9/1
N2 - We evaluated the efficacy of isavuconazole against cryptococcal meningitis. Treatment with either oral isavuconazole (120 mg/kg and 240 mg/kg twice a day [BID]) or fluconazole as the positive control significantly improved survival in mice infected intracranially with either Cryptococcus neoformans USC1597 or H99 and significantly reduced brain fungal burdens for both isolates. Concentrations of isavuconazole in plasma and brain tissue also demonstrated that the greatest improvements in survival and fungal burden were associated with elevated exposures.
AB - We evaluated the efficacy of isavuconazole against cryptococcal meningitis. Treatment with either oral isavuconazole (120 mg/kg and 240 mg/kg twice a day [BID]) or fluconazole as the positive control significantly improved survival in mice infected intracranially with either Cryptococcus neoformans USC1597 or H99 and significantly reduced brain fungal burdens for both isolates. Concentrations of isavuconazole in plasma and brain tissue also demonstrated that the greatest improvements in survival and fungal burden were associated with elevated exposures.
UR - http://www.scopus.com/inward/record.url?scp=84983335543&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84983335543&partnerID=8YFLogxK
U2 - 10.1128/AAC.00229-16
DO - 10.1128/AAC.00229-16
M3 - Article
C2 - 27324761
AN - SCOPUS:84983335543
SN - 0066-4804
VL - 60
SP - 5600
EP - 5603
JO - Antimicrobial agents and chemotherapy
JF - Antimicrobial agents and chemotherapy
IS - 9
ER -